| 000 | 01888 a2200565 4500 | ||
|---|---|---|---|
| 005 | 20250517122527.0 | ||
| 264 | 0 | _c20170808 | |
| 008 | 201708s 0 0 eng d | ||
| 022 | _a1872-7980 | ||
| 024 | 7 |
_a10.1016/j.canlet.2016.10.021 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWu, Fei | |
| 245 | 0 | 0 |
_aProstate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation. _h[electronic resource] |
| 260 |
_bCancer letters _c01 2017 |
||
| 300 |
_a207-214 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 |
_aCarbamates _xpharmacology |
| 650 | 0 | 4 |
_aCdc20 Proteins _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aCullin Proteins _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aCyclopentanes _xpharmacology |
| 650 | 0 | 4 |
_aDiamines _xpharmacology |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Resistance, Neoplasm |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xpharmacology |
| 650 | 0 | 4 | _aHeLa Cells |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMolecular Targeted Therapy |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 |
_aNuclear Proteins _xgenetics |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aProtein Interaction Domains and Motifs |
| 650 | 0 | 4 | _aProteolysis |
| 650 | 0 | 4 |
_aPyrimidines _xpharmacology |
| 650 | 0 | 4 |
_aRepressor Proteins _xgenetics |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTransfection |
| 650 | 0 | 4 | _aUbiquitination |
| 700 | 1 | _aDai, Xiangpeng | |
| 700 | 1 | _aGan, Wenjian | |
| 700 | 1 | _aWan, Lixin | |
| 700 | 1 | _aLi, Min | |
| 700 | 1 | _aMitsiades, Nicholas | |
| 700 | 1 | _aWei, Wenyi | |
| 700 | 1 | _aDing, Qiang | |
| 700 | 1 | _aZhang, Jinfang | |
| 773 | 0 |
_tCancer letters _gvol. 385 _gp. 207-214 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.canlet.2016.10.021 _zAvailable from publisher's website |
| 999 |
_c26549368 _d26549368 |
||